Estimating the risk of rabies transmission to humans in the U.S.: a delphi analysis
- Oncologic Briefs. // Dermatology Times;Jan2001, Vol. 22 Issue 1, p26
Reports global developments concerning skin diseases as of January 2001. Role of oral-oral contact plays in Kaposi sarcoma transmission; Accounts on the clinical trials for melanoma vaccines; Theoretical cause of melanoma.
- Understanding the risk of rabies. Ainsworth, Steve // Practice Nurse;1/16/2009, Vol. 37 Issue 1, p10
The article discusses the risk of rabies in Great Britain. Classical rabies was eradicated from the country in 1922, but there have been at least 23 deaths among people infected with rabies since then. Rabies is a zoonotic disease caused by a virus. The virus infects both domestic and wild...
- The vampire virus. Mims, Cedric // New Scientist;2/19/2011, Vol. 209 Issue 2800, p31
A letter to the editor is presented in response to an article by Paul Collins in the January 29, 2011 issue that was concerned with vampires.
- Prezentari. // Romanian Journal of Infectious Diseases;2012, Vol. 15 Issue 3, p121
No abstract available.
- Sample size calculation for multicentre efficacy trials of blood-stage malaria antigens. Bosomprah, Samuel // Malaria Journal;2013, Vol. 12 Issue 1, p1
Background: Sample size has increasingly become a prerequisite for grant approval. Study size calculations for multicentre trials are more complicated because these sites present different assumptions on incidence of disease expected in the control group; this then changes the mechanism of...
- Defining HIV Susceptibility to New Antiretroviral Agents--Darunavir. Haubrich, Richard // Journal of Infectious Diseases;10/15/2007, Vol. 196 Issue 8, p1125
The article presents the author's comment on issues concerning decisions-making in selection of antiretroviral agents for treatment of human papillomavirus (HPV) disease in various clinical settings. The author appreciated the study by Yumi Mitsuya and colleagues on Darunavir resistance...
- The use of highly active retroviral therapy to reduce HIV incidence at the population level. Anema, Aranka; Wood, Evan; Montaner, Julio S. G. // CMAJ: Canadian Medical Association Journal;7/1/2008, Vol. 179 Issue 1, p13
The author expresses his views on the highly active antiretroviral therapy as a possible drug in reducing human immunodeficiency syndrome (HIV) at population level. The author cites clinical trials showing that antiretroviral therapy has successfully prevents transmission of HIV from mother to...
- What kind of randomized trials do we need? Zwarenstein, Merrick; Treweek, Shaun // CMAJ: Canadian Medical Association Journal;5/12/2009, Vol. 180 Issue 10, p998
The article presents a reprint of the article regarding the use of the randomized trials (RCT), which appeared in the May 2009 issue of "Journal of Clinical Epidemiology." These randomized trials are embodied by the radically different attitudes of evaluating the pragmatic and explanatory...
- Insensitivity of paediatric HIV-1 subtype C viruses to broadly neutralising monoclonal antibodies raised against subtype B. Gray, Elin Solomonovna; Meyers, Tammy; Gray, Glenda; Montefiori, David Charles; Morris, Lynn // PLoS Medicine;Jul2006, Vol. 3 Issue 7, pe255
Background:A Phase I clinical trial has been proposed that uses neutralising monoclonal antibodies (MAbs) as passive immunoprophylaxis to prevent mother-to-child transmission of HIV-1 in South Africa. To assess the suitability of such an approach, we determined the sensitivity of...